Topics

Gracell Reports Positive Results from FasT CAR-19 Cell Gene Therapy

04:19 EDT 13 Sep 2019 | ChinaBio Today

Gracell, a Suzhou-Shanghai biotech, announced positive early results of its first-in-class FasT CAR-19 investigational cell gene therapy: in 24 patients, 23 (95.8%) achieved complete remission and 21 (87.5%) showed undetectable minimal residual disease (uMRD). All of the patients had relapsed/refractory B-ALL leukemia. Gracell's FasT CAR therapy reduces preparation time of the T-cells from two weeks to one day, lowering the cost. The results were announced during the CAR-TCR Summit currently being held in Boston. More details....

Share this with colleagues:

Original Article: Gracell Reports Positive Results from FasT CAR-19 Cell Gene Therapy

NEXT ARTICLE

More From BioPortfolio on "Gracell Reports Positive Results from FasT CAR-19 Cell Gene Therapy"

Quick Search

Relevant Topics

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Gene Therapy
Gene therapy is the use of DNA as a pharmaceutical agent to treat disease. It derives its name from the idea that DNA can be used to supplement or alter genes within an individual's cells as a therapy to treat disease. The most common form of gene th...